文献速递甲状腺与颈部外科

经皮乙醇消融治疗甲状腺乳头状癌淋巴结转移的长期结局

Ethanol ablation of papillary thyroid carcinoma nodal metastases: Long-term outcomes.
PubMed 文献 · Surgery · 2024-01-08

这项回顾性研究纳入2013至2018年接受经皮乙醇消融的117例甲状腺乳头状癌侧颈淋巴结转移患者,其中67例(57%)既往行侧颈清扫。中位随访5.5年,3例(3%)出现短暂神经相关并发症,33例(28%)复发;既往是否行侧颈清扫的复发率无显著差异(24% vs 31%,HR=1.27,95%CI 0.62-2.58,P=.514)。作者认为,经皮乙醇消融可能是有选择的低瘤负荷淋巴结复发患者的安全初始治疗方式。

要点

  • 117例侧颈淋巴结转移患者接受经皮乙醇消融,中位随访5.5年。
  • 3例(3%)出现短暂神经相关并发症,33例(28%)复发。
  • 既往侧颈清扫与未清扫者复发率无显著差异(24% vs 31%,HR=1.27,95%CI 0.62-2.58,P=.514)。

核心结论

  • 经皮乙醇消融可能是有选择的低瘤负荷侧颈淋巴结复发甲状腺乳头状癌患者的安全初始治疗方式。

研究设计与样本

  • 回顾性研究,纳入2013至2018年接受经皮乙醇消融的侧颈甲状腺乳头状癌淋巴结转移患者117例,其中67例(57%)既往行侧颈清扫。

主要发现

  • 经皮乙醇消融后中位随访5.5年(四分位距3.1-7.5),平均治疗1.4枚淋巴结(范围1-6)。
  • 3例(3%)出现短暂神经相关并发症。
  • 经皮乙醇消融后行侧颈清扫15例(含再次侧颈清扫),其中8例(53%)手术「困难」(7例既往行侧颈清扫),4例(27%)出现并发症(短暂神经功能障碍3例,淋巴漏1例)。
  • 33例(28%)复发甲状腺乳头状癌;既往行与未行侧颈清扫者复发率无显著差异(未行侧颈清扫24% vs 行侧颈清扫31%,HR=1.27,95%CI 0.62-2.58,P=.514)。

临床怎么用

  • 作者认为,经皮乙醇消融可能是有选择的低瘤负荷侧颈淋巴结复发甲状腺乳头状癌患者的安全初始治疗方式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Percutaneous ethanol ablation has emerged as a treatment for recurrent papillary thyroid carcinoma in the lateral neck after compartment-oriented therapeutic lymphadenectomy. However, the safety and utility of percutaneous ethanol ablation as a primary treatment modality for lateral neck metastases remains undefined. We aimed to investigate long-term outcomes of percutaneous ethanol ablation of lateral neck papillary thyroid carcinoma recurrence both with and without prior lymphadenectomy. METHODS: We conducted a retrospective study of patients with lateral neck papillary thyroid carcinoma treated with percutaneous ethanol ablation from 2013 to 2018. Patient characteristics, disease volume, morbidity, and recurrence (development of new lymphadenopathy within a percutaneous ethanol ablation-treated nodal compartment) were assessed. RESULTS: We identified 117 patients who underwent percutaneous ethanol ablation for papillary thyroid carcinoma lateral neck metastases-67 (57%) had a prior lateral neck dissection. Median follow-up after percutaneous ethanol ablation was 5.5 years (interquartile range 3.1-7.5). On average, 1.4 lymph nodes (range: 1-6) were treated. Three patients (3%) developed transient nerve-related complications after percutaneous ethanol ablation. Of 15 patients who underwent lateral neck dissection after percutaneous ethanol ablation (including patients undergoing repeat lateral neck dissection), dissection was "difficult" in 8 (53%) (7 of whom had previously undergone lateral neck dissection), and 4 (27%) developed complications (transient nerve dysfunction = 3, lymphatic leak = 1). Thirty-three patients (28%) developed recurrent papillary thyroid carcinoma. No difference in recurrence was seen between patients who did or did not undergo pre-percutaneous ethanol ablation lateral neck dissection (no pre-percutaneous ethanol ablation lateral neck dissection: 24%, pre-percutaneous ethanol ablation lateral neck dissection, 31%; hazard ratio = 1.27, 95% confidence interval 0.62-2.58; P = .514). CONCLUSION: Percutaneous ethanol ablation may be a safe primary treatment modality for papillary thyroid carcinoma lateral neck nodal recurrence in selected patients with low-volume nodal disease.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Lund S, Schmitz JJ, Foster T, et al. Ethanol ablation of papillary thyroid carcinoma nodal metastases: Long-term outcomes. Surgery. 2024. PMID: 38195302. doi:10.1016/j.surg.2023.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。